Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumab.

Gebrael G, Jo Y, Ozay ZI, Nandakumar V, Cigliola A, Tateo V, Lin E, Ostrowski M, Sayegh N, Murdock E, Mathew Thomas V, Gupta S, Agarwal N, Swami U.

Open source

DOI: 10.1177/23523735261437911
Published: 2026-01-01
Container: Bladder Cancer
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1177/23523735261437911,
  title = {Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumab.},
  author = {Gebrael G and  Jo Y and  Ozay ZI and  Nandakumar V and  Cigliola A and  Tateo V and  Lin E and  Ostrowski M and  Sayegh N and  Murdock E and  Mathew Thomas V and  Gupta S and  Agarwal N and  Swami U.},
  year = {2026},
  journal = {Bladder Cancer},
  doi = {10.1177/23523735261437911},
  url = {https://doi.org/10.1177/23523735261437911}
}

RIS

TY  - JOUR
TI  - Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumab.
AU  - Gebrael G
AU  -  Jo Y
AU  -  Ozay ZI
AU  -  Nandakumar V
AU  -  Cigliola A
AU  -  Tateo V
AU  -  Lin E
AU  -  Ostrowski M
AU  -  Sayegh N
AU  -  Murdock E
AU  -  Mathew Thomas V
AU  -  Gupta S
AU  -  Agarwal N
AU  -  Swami U.
PY  - 2026
JO  - Bladder Cancer
DO  - 10.1177/23523735261437911
UR  - https://doi.org/10.1177/23523735261437911
ER  -

APA

G, G., Y, J., ZI, O., V, N., A, C., V, T., E, L., M, O., N, S., E, M., V, M. T., S, G., N, A., & U., S. (2026). Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumab.. Bladder Cancer. https://doi.org/10.1177/23523735261437911

Source records

europe-pmc · retrieved 2026-09-27T05:54:06.149Z
doaj · retrieved 2026-09-27T05:54:06.159Z